Otvos James D. 4
4 · LIPOSCIENCE INC · Filed Jan 30, 2013
Insider Transaction Report
Form 4
LIPOSCIENCE INCLPDX
Otvos James D.
EVP, Chief Scientific Officer
Transactions
- Conversion
Common Stock
2013-01-30+7,370→ 472,890 total - Conversion
Series C Convertible Preferred Stock
2013-01-30−12,652→ 0 total→ Common Stock (7,370 underlying)
Holdings
- 180,167(indirect: By Spouse)
Common Stock
Footnotes (3)
- [F1]Represents shares received upon conversion of shares of Series C convertible preferred stock.
- [F2]Effective immediately prior to the closing of the issuer's initial public offering of its common stock, each share of Series C convertible preferred stock automatically converted into approximately 0.582 shares of common stock. The convertible preferred stock had no expiration date.
- [F3]The Series C Convertible Preferred Stock converted into common stock on an approximately 0.582-for-1 basis and had no expiration date.